LONG MINI-FUTURE - VERTEX PHARMACEUTICALS | Market Closed - Boerse Frankfurt Warrants 01:43:19 2024-07-11 pm EDT | ||
| 12.68 EUR | +1.12% |
|
| Current month | +10.74% | ||
| 1 month | +5.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 12.68 | +1.12% |
| 24-07-10 | 12.54 | +2.70% |
| 24-07-09 | 12.21 | +3.83% |
| 24-07-08 | 11.76 | +4.63% |
| 24-07-05 | 11.24 | +3.69% |
Real-time Boerse Frankfurt Warrants
Last update July 11, 2024 at 01:43 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM6W78 |
| ISIN | DE000VM6W787 |
| Date issued | 2023-12-12 |
| Strike | 356.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.68 € |
|---|---|
| Lowest since issue | 1.92 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
492.1
USD
Average target price
473.1
USD
Spread / Average Target
-3.87%
- Stock Market
- Certificates
- Certificat
